Lexicon said that LX1031 was found to be well-tolerated at all doses tested in the recently completed phase Ia trial.
“The safety and pharmacokinetic profile exhibited by LX1031 in the initial phase Ia trial is consistent with our observations in preclinical studies,” said Philip Brown, vice president of clinical development at Lexicon.
The phase Ib trial is a randomized, double-blind, ascending multiple-dose study designed to evaluate safety and tolerability of LX1031 after multiple doses in approximately 40 healthy volunteers. Lexicon expects data from this clinical trial in the third quarter of 2007.
Irritable bowel syndrome is a disorder most commonly characterized by cramping, abdominal pain, bloating, constipation or diarrhea.